All In Biotech

NDA 211302 · Recordati Rare

Cystadrops

Cysteamine Hydrochloride · Ophthalmic

Last checked: Nov 19, 2026Latest source record: Aug 19, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Aug 19, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

33

8 Phase 3, 2 recruiting

FAERS reports

240

157 serious, 19 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 6, 2025.

CYSTADROPS is a cystine-depleting agent indicated for the treatment of corneal cystine crystal deposits in adults and children with cystinosis. CYSTADROPS is a cystine-depleting agent indicated for the treatment of corneal cystine crystal deposits in adults and children with cystinosis. ( 1 )

Mechanism: Cysteamine acts as a cystine-depleting agent by converting cystine to cysteine and cysteine-cysteamine mixed disulfides and reduces corneal cystine crystal accumulation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 19, 2020 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • CYSTADROPS · CYSTEAMINE HYDROCHLORIDE EQ 0.37% BASE · SOLUTION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Cysteamine" as an intervention, any sponsor and status, largest first.

All 33 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • eye irritation41
  • eye pain26
  • death15
  • vision blurred14
  • vomiting14
  • ocular hyperaemia13
  • off label use9
  • amino acid level increased8
  • corneal neovascularisation8
  • pneumonia8
  • treatment noncompliance8
  • dehydration7

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20152
20161
20171
20181
20193
202021
202140
202240
202347
202457
202518
20269

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Cystadrops (Cysteamine HCl)

2024 spending

$2.7M

Beneficiaries

30

285 claims

Per beneficiary

$89,019

$462.43 per unit

View as table
YearSpending
2020$166,226
2021$2,925,445
2022$2,909,441
2023$2,301,078
2024$2,670,557

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 94 on PubMed

Sponsor: Recordati Rare

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.